The National Institutes of Health will conduct two clinical trials of the smallpox drug TPOXX (tecovirimat) —— one in the Democratic Republic of the Congo and another in the United States — to see whether the drug can be safely and effectively used to treat monkeypox, including in the outpatient setting, the White House said in a fact sheet published Thursday (Aug. 11). The announcement follows the White House’s publication last month of its broader $140 million monkeypox research plan...